beatandraise : SEC Filings Research with AI

beatandraise.com

2.2.0.25falsefalse001100 - Disclosure - Acquisition of King Pharmaceuticals Inctruefalsefalse1falsefalseUSDfalsefalse1/1/2011 - 4/3/2011 USD ($) USD ($) / shares $Cur_3mos_20110403http://www.sec.gov/CIK0000078003duration2011-01-01T00:00:002011-04-03T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDperShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PercentStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2true0us-gaap_BusinessCombinationsAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalseAcquisition of King Pharmaceuticals Inc [Abstract]3false0us-gaap_BusinessCombinationDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <a name="xbrlnote3"><b><u><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note 3. Acquisition of King Pharmaceuticals, Inc.</font></u></b></a> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 31, 2011 (the acquisition date), we completed our tender offer for all of the outstanding shares of common stock of King at a purchase price of $14.25 per share in cash and acquired approximately 92.5% of the outstanding shares. On February 28, 2011, we acquired all of the remaining shares of King for $14.25 per share in cash. As a result, the total fair value of consideration transferred for King was approximately $3.6 billion in cash ($3.2 billion, net of cash acquired).</font> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">King’s principal businesses consist of a prescription pharmaceutical business focused on delivering new formulations of pain treatments designed to discourage common methods of misuse and abuse; the Meridian auto-injector business for emergency drug delivery, which develops and manufactures the EpiPen; an established products portfolio; and an animal health business that offers a variety of feed-additive products for a wide range of species.</font> </div> <div style="display: block; text-indent: 0pt">   </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes the provisional recording, primarily at fair value, of the assets acquired and liabilities assumed as of the acquisition date:</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> </font> </div> <div> <hr size="2" width="100%" align="left" style="COLOR: black"/> </div> <div align="left"> <table width="100%" cellspacing="0" cellpadding="0" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td style="border-bottom: black 2px solid" valign="bottom" width="84%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">(millions of dollars)</font> </div> </td> <td style="padding-bottom: 2px" valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="text-indent: 0pt; border-bottom: black 2px solid; margin-left: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="14%" align="right" colspan="2"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amounts</font> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Recognized as of</font> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Acquisition Date</font> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Provisional)</font> </div> </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td valign="bottom" width="84%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="14%" colspan="2"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td valign="bottom" width="84%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Working capital, excluding inventories</font> </div> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td> <td valign="bottom" width="13%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">210</font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td valign="bottom" width="84%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Inventories</font> </div> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="13%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">340</font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td valign="bottom" width="84%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property, plant and equipment</font> </div> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="13%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">413</font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td valign="bottom" width="84%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Identifiable intangible assets, excluding in-process research and development</font> </div> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="13%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,781</font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td valign="bottom" width="84%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In-process research and development</font> </div> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="13%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">301</font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td valign="bottom" width="84%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net tax accounts</font> </div> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="13%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(384</font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </td> </tr> <tr> <td style="padding-bottom: 2px" valign="bottom" width="84%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">All other long-term assets and liabilities, net</font> </div> </td> <td style="padding-bottom: 2px" valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 2px solid" valign="bottom" width="13%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">114</font> </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td valign="bottom" width="84%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total identifiable net assets</font> </div> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="13%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,775</font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td style="padding-bottom: 2px" valign="bottom" width="84%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Goodwill</font> </div> </td> <td style="padding-bottom: 2px" valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 2px solid" valign="bottom" width="13%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">780</font> </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td style="border-bottom: black 6px double " valign="bottom" width="84%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net assets acquired/total consideration transferred</font> </div> </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td> <td style="border-bottom: black 6px double " valign="bottom" width="13%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,555</font> </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $200 million, virtually all of which is expected to be collected.</font> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of King includes the following:</font> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div> <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 9pt"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">●</font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the expected synergies and other benefits that we believe will result from combining the operations of King with the operations of Pfizer;</font> </div> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div> <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 9pt"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">●</font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">any intangible assets that do not qualify for separate recognition, as well as future, yet unidentified projects and products; and</font> </div> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div> <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 9pt"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">●</font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the value of the going-concern element of King’s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately).</font> </div> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Goodwill is not amortized and is not deductible for tax purposes. While the allocation of goodwill among reporting units is not complete, we expect that substantially all of the goodwill will be related to our biopharmaceutical reporting units (see </font><i><font style="DISPLAY: inline; FONT-STYLE: italic">Note 11. Goodwill and Other Intangible Assets </font></i><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">for additional information).</font> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The assets and liabilities arising from contingencies recognized at acquisition date, which are subject to change, are not significant to Pfizer’s financial statements.</font> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change:</font> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div> <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 9pt"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">●</font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amounts for intangibles, inventory and property, plant and equipment (PP&E), pending finalization of valuation efforts for acquired intangible assets as well as the completion of certain physical inventory counts and the confirmation of the physical existence and condition of certain PP&E assets.</font> </div> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div> <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 9pt"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">●</font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amounts for environmental contingencies, pending the finalization of our assessment and valuation of environmental matters.</font> </div> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div> <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 9pt"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">●</font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amounts for legal contingencies, pending the finalization of our examination and evaluation of the portfolio of filed cases.</font> </div> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div> <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 9pt"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">●</font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amounts for income tax assets, receivables and liabilities pending the filing of King’s pre-acquisition tax returns and the receipt of information from taxing authorities, which may change certain estimates and assumptions used.</font> </div> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div> <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 9pt"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">●</font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The allocation of goodwill among reporting units.</font> </div> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="justify">   </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table presents information for King that is included in Pfizer’s condensed consolidated statement of income from the acquisition date, January 31, 2011, through Pfizer’s first-quarter 2011 domestic and international quarter-ends:</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> </font> </div> <div> <hr size="2" width="100%" align="left" style="COLOR: black"/> </div> <div align="left"> <table width="100%" cellspacing="0" cellpadding="0" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td style="border-bottom: black 2px solid" valign="bottom" width="82%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">(millions of dollars)</font> </div> </td> <td style="padding-bottom: 2px" valign="bottom" width="1%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 2px solid" valign="bottom" width="16%" align="right" colspan="2"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">King’s Operations </font> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Included in Pfizer’s First </font> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Quarter 2011 Results</font> </div> </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td valign="bottom" width="82%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="16%" colspan="2"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td valign="bottom" width="82%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenues</font> </div> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td> <td valign="bottom" width="15%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">224</font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td style="border-bottom: black 6px double " valign="bottom" width="82%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loss from continuing operations attributable to Pfizer Inc. common shareholders</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font> </div> </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 6px double " valign="bottom" width="15%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(69</font> </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </td> </tr> </table> </div> <div align="left"> <table width="100%" cellspacing="0" cellpadding="0" border="0" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 36pt" width="2%"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(a)</font> </div> </td> <td width="98%"> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Includes purchase accounting adjustments related to the fair value adjustments for acquisition-date inventory estimated to have been sold ($57 million pre-tax), amortization of identifiable intangible assets acquired from King ($29 million pre-tax) and restructuring and integration costs ($95 million pre-tax).</font> </div> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="justify">   </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table presents supplemental pro forma information as if the acquisition of King had occurred on January 1, 2010: </font> <div> <hr size="2" width="100%" align="left" style="COLOR: black"/> </div> </div> <div align="left"> <table width="100%" cellspacing="0" cellpadding="0" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td style="padding-bottom: 2px" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font> </td> <td style="padding-bottom: 2px" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 2px solid" valign="bottom" colspan="6"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pro Forma Consolidated Results</font> </div> </td> <td style="border-bottom: black 2px solid" valign="bottom" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td style="padding-bottom: 2px" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font> </td> <td style="padding-bottom: 2px" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 2px solid" valign="bottom" colspan="6"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three Months Ended</font> </div> </td> <td style="border-bottom: black 2px solid" valign="bottom" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td style="border-bottom: black 2px solid" valign="bottom" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">(millions of dollars, except per share  data)</font> </div> </td> <td style="text-indent: 0pt; margin-left: 0pt; padding-bottom: 2px; MARGIN-RIGHT: 0pt" valign="bottom" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="text-indent: 0pt; border-bottom: black 2px solid; margin-left: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" align="right" colspan="2"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 3,</font> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font> </div> </td> <td style="text-indent: 0pt; border-bottom: black 2px solid; margin-left: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="text-indent: 0pt; margin-left: 0pt; padding-bottom: 2px; MARGIN-RIGHT: 0pt" valign="bottom" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="text-indent: 0pt; border-bottom: black 2px solid; margin-left: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" align="right" colspan="2"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 4,</font> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font> </div> </td> <td style="text-indent: 0pt; border-bottom: black 2px solid; margin-left: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">  </font> </td> <td valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" colspan="2"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" colspan="2"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenues</font> </div> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td> <td valign="bottom" width="9%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,611</font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td> <td valign="bottom" width="9%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,949</font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Income from continuing operations attributable to Pfizer Inc. common shareholders</font> </div> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="9%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,313</font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td valign="bottom" width="9%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,910</font> </td> <td valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> <tr> <td style="border-bottom: black 6px double " valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Diluted earnings per share attributable to Pfizer Inc. common shareholders</font> </div> </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 6px double " valign="bottom" width="9%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.29</font> </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> <td style="border-bottom: black 6px double " valign="bottom" width="9%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.24</font> </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="justify">   </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The unaudited pro forma consolidated results do not purport to project the future results of operations of the combined company nor do they reflect the expected realization of any cost savings associated with the acquisition. The unaudited pro forma consolidated results reflect the historical financial information of Pfizer and King, adjusted for the following pro forma pre-tax amounts:</font> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div> <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 9pt"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">●</font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Elimination of King’s historical intangible asset amortization expense ($6 million in 2011 and $41 million in 2010).</font> </div> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div> <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 9pt"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">●</font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additional amortization expense (approximately $14 million in 2011 and $43 million in 2010) related to the fair value of identifiable intangible assets acquired.</font> </div> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div> <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 9pt"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">●</font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additional depreciation expense (approximately $1 million in 2011 and $3 million in 2010) related to the fair value adjustment to property, plant and equipment acquired.</font> </div> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div> <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 9pt"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">●</font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Adjustment related to the fair value adjustments to acquisition-date inventory estimated to have been sold (elimination of $57 million charge in 2011 and addition of $57 million charge in 2010).</font> </div> </td> </tr> </table> </div> <div style="display: block; text-indent: 0pt"> <br/> </div> <div> <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 9pt"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">●</font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Adjustment for acquisition-related costs directly attributable to the acquisition (elimination of $117 million of charges in 2011 and addition of $117 million of charges in 2010, reflecting charges incurred by both King and Pfizer).</font> </div> </td> </tr> </table> </div> </div> </div>Note 3. Acquisition of King Pharmaceuticals, Inc. On January 31, 2011 (the acquisitionfalsefalsefalsefalsefalseOthernonnum:textBlockItemTypenaThe entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51, 52 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1500-128463 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7000-128479 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6927-128479 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7008-128479 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1490-128463 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6996-128479 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Appendix F -Paragraph F4 -Subparagraph e Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1383-128463 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1392-128463 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1497-128463 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 67-73 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1524-128463 Reference 17: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 88-16 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 18: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1486-128463 Reference 19: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472 falsefalseAcquisition of King Pharmaceuticals Inc [Text Block]12Acquisition of King Pharmaceuticals IncUnKnownUnKnownUnKnownUnKnownfalsetrue